NCT01580241Active, not recruiting
Serum DCAMKL1 Pre and Post Treatment in Patients With Pancreatic Cancer
Expression Patterns of Stem Cell Marker Doublecortin and CaM Kinase-Like-1 (DCAMKL-1) in Human Pancreatic Adenocarcinoma
Source: ClinicalTrials.gov · Last updated 1 Apr 2026
Brief summary (registry, in English)
The investigators believe DCAMKL-1 is a stem cell tumor marker and is elevated in patients with pancreatic cancer. The investigators would like to analyze its expression pre and post treatment, to gauge the correlation between current pancreatic cancer therapies and the expression of DCAMKL-1
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 60 (estimated)
- First submitted
- 17 Apr 2012
- Start date
- 1 Oct 2010
- Primary completion date
- 31 Jul 2015
- Lead sponsor
- University of Oklahoma
- Diseases
- Pancreatic cancer
- NCT number
- NCT01580241
What you commit to
- Study type: Observational
- Planned participants: 60
- From 1 Oct 2010 to the primary completion date, 31 Jul 2015
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Age
- age \< 18, history of other types of cancer
Who the study is looking for
- pancreatic cancer
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Stephensen Cancer Center Coordinator of this site? Confirm its status | Oklahoma City | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.